Relmada Therapeutics discloses director stock appreciation rights grant

Relmada Therapeutics, Inc. reported an insider equity award to one of its directors.

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. reported an insider equity award to one of its directors. On 12/12/2025, the director received stock appreciation rights tied to 164,000 shares of common stock with a base price of $4.06 per share.

These stock appreciation rights begin vesting in 16 equal quarterly installments starting on March 12, 2026, and are scheduled to expire on December 12, 2035. The award was reported as directly owned by the director.

Insider Trade Summary

Grant/Award: 164,000 shares

Grant/Award 1 txn

Insider CASAMENTO CHARLES J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights	164,000	$0.00	$0.00

Holdings After Transaction: Stock Appreciation Rights — 164,000 contracts (Direct)

Footnotes (1)

1. F1. The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Relmada Therapeutics (RLMD) report?

Relmada Therapeutics reported that a director received stock appreciation rights on 12/12/2025, tied to shares of the company’s common stock.

How many stock appreciation rights were granted in this Relmada Therapeutics (RLMD) filing?

The director was granted stock appreciation rights covering 164,000 shares of Relmada Therapeutics common stock.

What is the base price of the Relmada Therapeutics (RLMD) stock appreciation rights?

The stock appreciation rights have a base price of $4.06 per underlying share of common stock.

When do the Relmada Therapeutics (RLMD) stock appreciation rights start vesting?

The stock appreciation rights vest in 16 equal quarterly installments beginning on March 12, 2026.

When do the granted stock appreciation rights for Relmada Therapeutics (RLMD) expire?

The stock appreciation rights are scheduled to expire on December 12, 2035, if not exercised earlier under their terms.

What is the reporting person’s relationship to Relmada Therapeutics (RLMD)?

The reporting person is identified as a director of Relmada Therapeutics, Inc., and the form is filed for one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/16/2025 - 09:28 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASAMENTO CHARLES J

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$4.06	12/12/2025		A		164,000		03/12/2026(1)	12/12/2035	Common Stock	164,000	$0	164,000	D

Explanation of Responses:

1. The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

	/s/ Charles J. Casamento	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.